INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 43h ago
HOUSE PTR3h ago
SEC 13F3h ago
ROBINHOOD CHAIN3h ago
Corporate insider
TP

Tak Paul Peter

Director, Chief Executive OfficerCIK 0001873905

EDGAR filingsOpen in network
Disclosed transactions4
Buys / sells0 / 2
Max Insider Score26
Connections1with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
10
TP
Tak Paul PeterDirector, Chief Executive Officer
CADLCandel Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$194K
125.0K sh
Sep 10, 2026Sep 11, 2026
traded Sep 10, 2026
+1dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Candel Therapeutics, Inc.Director, Chief Executive Officer · Sep 11, 2026
26
TP
Tak Paul PeterDirector, Chief Executive Officer
CADLCandel Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL
$2.54M
220.9K sh
Sep 10, 2026
Sep 11, 2026
traded Sep 10, 2026
+1d
SEC FORM 4

Evidence

15
TP
Tak Paul PeterDirector, Chief Executive Officer
CADLCandel Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$621K
59.4K sh
Sep 11, 2026Sep 11, 2026
traded Sep 11, 2026
+0dSEC FORM 4

Evidence

3
TP
Tak Paul PeterDirector, Chief Executive Officer
CADLCandel Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
125.0K sh
Sep 10, 2026Sep 11, 2026
traded Sep 10, 2026
+1dSEC FORM 4

Evidence